DMAC

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

DiaMedica Therapeutics Inc

NASDAQ | DMAC

5.92

USD

$0.00

(

0.00%

)

At Close (As of Nov 7, 2025)

$321.51M

Market Cap

-

P/E Ratio

-0.69

EPS

$7.49

52 Week High

$3.19

52 Week Low

HEALTHCARE

Sector

DMAC Chart

Recent Chart
Price Action

DMAC Technicals

Tags:

DMAC Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$39K
Total Revenue $0
Cost Of Revenue $39K
Costof Goods And Services Sold $39K
Operating Income -$27M
Selling General And Administrative $7.6M
Research And Development $19M
Operating Expenses $27M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $39K
Income Before Tax -$24M
Income Tax Expense $30K
Interest And Debt Expense -
Net Income From Continuing Operations -$24M
Comprehensive Income Net Of Tax -
Ebit -$24M
Ebitda -$24M
Net Income -$24M

Revenue & Profitability

Earnings Performance

DMAC Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $46M
Total Current Assets $45M
Cash And Cash Equivalents At Carrying Value $3M
Cash And Short Term Investments $3M
Inventory -
Current Net Receivables $236K
Total Non Current Assets $1.7M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $41M
Other Current Assets $227K
Other Non Current Assets -
Total Liabilities $5.6M
Total Current Liabilities $5.4M
Current Accounts Payable $940K
Deferred Revenue -
Current Debt -
Short Term Debt $103K
Total Non Current Liabilities $237K
Capital Lease Obligations $340K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $340K
Other Current Liabilities $4.3M
Other Non Current Liabilities -
Total Shareholder Equity $41M
Treasury Stock -
Retained Earnings -$140M
Common Stock -
Common Stock Shares Outstanding $40M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$22M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $39K
Capital Expenditures $25K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $8.6M
Cashflow From Financing $12M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$24M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$39K
Total Revenue $0
Cost Of Revenue $39K
Costof Goods And Services Sold $39K
Operating Income -$27M
Selling General And Administrative $7.6M
Research And Development $19M
Operating Expenses $27M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $39K
Income Before Tax -$24M
Income Tax Expense $30K
Interest And Debt Expense -
Net Income From Continuing Operations -$24M
Comprehensive Income Net Of Tax -
Ebit -$24M
Ebitda -$24M
Net Income -$24M

DMAC News

DMAC Profile

DiaMedica Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Minneapolis, Minnesota, specialized in developing innovative therapies for neurological and kidney diseases. The company's lead candidate, DM199, targets the enhancement of renal function in patients suffering from diabetic kidney disease, showcasing its commitment to addressing critical unmet medical needs. With a robust pipeline and a strong emphasis on clinical innovation, DiaMedica is strategically positioned to advance transformative treatment options, aiming to significantly improve patient outcomes within the biopharmaceutical sector.

BKYI
+51.56%
$0.96
RUBI
+39.37%
$0.31
AZI
-4.05%
$0.09
NVDA
+0.03%
$188.15
ASST
+4.13%
$1.51
ACHR
-7.88%
$8.18
BYND
+16.80%
$1.39
PFE
+0.97%
$24.85
ONDS
+10.66%
$5.81
TSLA
-3.67%
$429.52
VHAI
0.00%
$0.00
INTC
+2.38%
$38.13
PLUG
-4.92%
$2.50
RIVN
-1.29%
$15.22
GRAB
-1.24%
$5.56
F
+1.82%
$13.21
SOFI
+3.86%
$28.21
DNN
0.00%
$2.56
PLTR
+1.64%
$177.93
SNAP
+2.43%
$8.20
AAL
+3.80%
$13.65
BITF
-0.81%
$3.66
AXDX
-61.36%
$0.03
WTO
-7.52%
$0.04
NIO
-4.32%
$6.85
T
+0.34%
$24.82
BURU
-6.81%
$0.27
DVLT
+24.26%
$1.69
CHR
+0.15%
$0.06
ETHD
-9.69%
$4.38
RGTI
-1.71%
$33.77
BTG
+2.76%
$3.90
PBR
+5.88%
$12.85
JOBY
+3.98%
$14.89
PRMB
-18.64%
$14.40
AMD
-1.75%
$233.54
ADAP
-15.14%
$0.05
HOOD
-10.80%
$127.08
QBTS
+3.94%
$29.51
SOUN
-0.63%
$14.14
IONZ
-6.57%
$3.55
IREN
-6.94%
$62.31
NVTS
-11.26%
$7.84
AAPL
-0.48%
$268.47
KVUE
+2.61%
$16.89
RXRX
-1.32%
$4.55
MARA
-2.41%
$15.57
NEHC
+6.52%
$6.04
YDKG
-3.72%
$0.04
HIMS
-5.05%
$41.52
EPWK
+1.42%
$0.07
WULF
-2.38%
$13.94
MTVA
+6.30%
$0.90
BTBT
+3.63%
$3.14
DKNG
+8.64%
$30.40
EOSE
+19.42%
$18.26
XPEV
+9.63%
$23.89
BMNR
+7.69%
$40.24
BAC
-0.13%
$53.22
RMBL
+60.50%
$3.21
ABEV
+1.45%
$2.43
RIG
+1.92%
$3.97
CIFR
-5.34%
$20.54
ADD
-25.47%
$0.05
SMR
-8.04%
$29.85
NOK
-0.72%
$6.86
GOOGL
+0.15%
$284.75
TLRY
-5.46%
$1.21
SRM
+53.27%
$10.30
GPUS
+0.67%
$0.37
TTD
-6.31%
$43.00
QS
+4.49%
$16.61
ORGO
+44.73%
$5.63
SMCI
-1.42%
$39.76
CMG
+0.01%
$30.56
BBD
-0.56%
$3.51
PINS
+2.05%
$26.28
IONQ
+3.25%
$59.30
AMZN
+0.02%
$243.09
PLTZ
+13.94%
$7.11
FIG
-3.98%
$44.15
VALE
-0.69%
$12.14
WBD
+1.11%
$22.67
MU
-0.17%
$237.92
AMC
-7.50%
$2.40
PTON
+14.15%
$7.66
MTC
-6.85%
$2.58
RF
+2.18%
$24.84
IOVA
-0.43%
$2.29
META
+0.44%
$621.71
CGC
+7.33%
$1.17
WLGS
-5.57%
$0.04
HBAN
+1.75%
$15.69
CAN
+5.30%
$1.19
VZ
+0.55%
$40.04
QUBT
-2.20%
$12.86
NGD
+1.58%
$7.03
CLSK
+1.10%
$15.57
ETWO
0.00%
$3.30
AMCR
+1.76%
$8.36
BKYI
+51.56%
$0.96
RUBI
+39.37%
$0.31
AZI
-4.05%
$0.09
NVDA
+0.03%
$188.15
ASST
+4.13%
$1.51
ACHR
-7.88%
$8.18
BYND
+16.80%
$1.39
PFE
+0.97%
$24.85
ONDS
+10.66%
$5.81
TSLA
-3.67%
$429.52
VHAI
0.00%
$0.00
INTC
+2.38%
$38.13
PLUG
-4.92%
$2.50
RIVN
-1.29%
$15.22
GRAB
-1.24%
$5.56
F
+1.82%
$13.21
SOFI
+3.86%
$28.21
DNN
0.00%
$2.56
PLTR
+1.64%
$177.93
SNAP
+2.43%
$8.20
AAL
+3.80%
$13.65
BITF
-0.81%
$3.66
AXDX
-61.36%
$0.03
WTO
-7.52%
$0.04
NIO
-4.32%
$6.85
T
+0.34%
$24.82
BURU
-6.81%
$0.27
DVLT
+24.26%
$1.69
CHR
+0.15%
$0.06
ETHD
-9.69%
$4.38
RGTI
-1.71%
$33.77
BTG
+2.76%
$3.90
PBR
+5.88%
$12.85
JOBY
+3.98%
$14.89
PRMB
-18.64%
$14.40
AMD
-1.75%
$233.54
ADAP
-15.14%
$0.05
HOOD
-10.80%
$127.08
QBTS
+3.94%
$29.51
SOUN
-0.63%
$14.14
IONZ
-6.57%
$3.55
IREN
-6.94%
$62.31
NVTS
-11.26%
$7.84
AAPL
-0.48%
$268.47
KVUE
+2.61%
$16.89
RXRX
-1.32%
$4.55
MARA
-2.41%
$15.57
NEHC
+6.52%
$6.04
YDKG
-3.72%
$0.04
HIMS
-5.05%
$41.52
EPWK
+1.42%
$0.07
WULF
-2.38%
$13.94
MTVA
+6.30%
$0.90
BTBT
+3.63%
$3.14
DKNG
+8.64%
$30.40
EOSE
+19.42%
$18.26
XPEV
+9.63%
$23.89
BMNR
+7.69%
$40.24
BAC
-0.13%
$53.22
RMBL
+60.50%
$3.21
ABEV
+1.45%
$2.43
RIG
+1.92%
$3.97
CIFR
-5.34%
$20.54
ADD
-25.47%
$0.05
SMR
-8.04%
$29.85
NOK
-0.72%
$6.86
GOOGL
+0.15%
$284.75
TLRY
-5.46%
$1.21
SRM
+53.27%
$10.30
GPUS
+0.67%
$0.37
TTD
-6.31%
$43.00
QS
+4.49%
$16.61
ORGO
+44.73%
$5.63
SMCI
-1.42%
$39.76
CMG
+0.01%
$30.56
BBD
-0.56%
$3.51
PINS
+2.05%
$26.28
IONQ
+3.25%
$59.30
AMZN
+0.02%
$243.09
PLTZ
+13.94%
$7.11
FIG
-3.98%
$44.15
VALE
-0.69%
$12.14
WBD
+1.11%
$22.67
MU
-0.17%
$237.92
AMC
-7.50%
$2.40
PTON
+14.15%
$7.66
MTC
-6.85%
$2.58
RF
+2.18%
$24.84
IOVA
-0.43%
$2.29
META
+0.44%
$621.71
CGC
+7.33%
$1.17
WLGS
-5.57%
$0.04
HBAN
+1.75%
$15.69
CAN
+5.30%
$1.19
VZ
+0.55%
$40.04
QUBT
-2.20%
$12.86
NGD
+1.58%
$7.03
CLSK
+1.10%
$15.57
ETWO
0.00%
$3.30
AMCR
+1.76%
$8.36
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.